<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary arterial hypertension associated with human immunodeficiency virus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary arterial hypertension associated with human immunodeficiency virus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary arterial hypertension associated with human immunodeficiency virus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ieong, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harrison W Farber, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human immunodeficiency virus (HIV) infection can be complicated by pulmonary hypertension (PH). The World Health Organization (WHO) classifies patients with PH into five groups based upon etiology  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Patients in the first group are considered to have pulmonary <strong>arterial</strong> hypertension (group 1 PAH), while patients in the remaining four groups are considered to have PH (group 2, 3, 4, and 5 PH). When all five groups are discussed collectively, the term PH is used. HIV-related PAH (HIV-PAH) belongs to group 1.</p><p>In this topic review, the prevalence, pathogenesis, clinical diagnostic evaluation, and treatment of HIV-PAH are discussed. PH that is unrelated to HIV infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>HIV-PAH is a rare complication of HIV infection, occurring in approximately 1 out of every 200 HIV-infected patients (0.5 percent) [<a href="#rid2">2-11</a>]. This is 100 to 1000-times greater than the prevalence of PAH in individuals without HIV infection. However, studies likely underestimate the true prevalence of HIV-PAH because patients with asymptomatic PAH are not included. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Epidemiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Best supporting this prevalence is a prospective study of 7648 patients with HIV, which found a prevalence of right-heart catheterization-confirmed HIV-PAH of 0.5 percent [<a href="#rid6">6</a>]. This study, which was performed from 2004 to 2005 (after the introduction of potent antiretroviral therapy [ART]), reported a similar prevalence to that which was reported in studies performed prior to the use of effective ART, suggesting that ART has not altered the prevalence of HIV-PAH [<a href="#rid6">6,10</a>]. (See <a class="local">'Antiretroviral therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smaller cohort studies have demonstrated prevalence rates of HIV-PAH as high as 2.6 to 14 percent using echocardiography [<a href="#rid9">9,12-14</a>]. However, the observational design of many of these studies and the limitations of echocardiography in the diagnosis of PAH make such assessments of prevalence unreliable [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with high viral loads and low CD-4 count have a higher prevalence of increased pulmonary artery systolic pressures ≥40 mmHg and mortality than uninfected patients [<a href="#rid16">16</a>]. However, patients with HIV who did not have pulmonary hypertension were not included in this analysis.</p><p></p><p>Reflective of our practice, PAH (ie, group 1 PAH) is probably no longer the predominant form of pulmonary hypertension (PH) in patients with HIV. With the advent of ART, HIV-infected patients are living longer allowing for common chronic cardiac [<a href="#rid17">17</a>] and respiratory diseases to manifest. As a result, PH due to left-heart disease (group 2 PH) and/or lung disease (group 3 PH) is expected to increase. PH due to pulmonary venoocclusive disease (also group 1) is rare in general but has also been reported. (See  <a class="medical medical_review" href="/d/html/3699.html" rel="external">"Cardiac and vascular disease in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/8269.html" rel="external">"Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Miscellaneous'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathology of HIV-PAH is indistinguishable from that seen in patients who have idiopathic PAH (IPAH), and thus, similar pathogenetic mechanisms are likely involved [<a href="#rid18">18,19</a>]. Additional viral and host factors likely play important roles in patients with HIV  (<a class="graphic graphic_figure graphicRef116800" href="/d/graphic/116800.html" rel="external">figure 1</a>). However, the relative contributions of each are difficult to discern because many patients with HIV infection have coexisting conditions that are independently associated with PAH (eg, intravenous drug use, chronic liver disease, cocaine, and stimulants) [<a href="#rid2">2,20,21</a>]. Mechanisms specific to HIV infection are discussed here, while general pathology and pathogenetic mechanisms in IPAH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Pathogenetic mechanisms'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">HIV-related factors</span><span class="headingEndMark"> — </span>While HIV is not known to infect endothelial cells, the following HIV-associated proteins may contribute to the development of HIV-PAH:</p><p class="bulletIndent1"><span class="glyph">●</span>gp120 – gp120 is an HIV surface glycoprotein that stimulates secretion of endothelin-1, a molecule known to contribute to IPAH [<a href="#rid22">22</a>]. A similar contribution to HIV-PAH, is supported by the observation that circulating monocytes from patients with HIV have increased endothelin-1 gene expression [<a href="#rid22">22</a>]. Oxidative stress induced by gp120 (and tat) may lead to endothelial dysfunction and vascular injury in HIV-infected rats [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tat – Tat is an HIV transactivator that downregulates the expression of bone morphogenetic protein receptor type II (BMPR2), a molecule that plays a role in the development of IPAH [<a href="#rid24">24</a>]. In support, BMPR2 protein expression was found to be downregulated in HIV-infected drug users compared with HIV-infected or uninfected drug users [<a href="#rid21">21</a>]. Tat has also been implicated in the proliferation of pulmonary artery smooth muscle cells [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Genetic mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nef – Nef is an HIV adaptor protein that exists in alveolar mononuclear cells and endothelial cells of patients who have HIV-PAH [<a href="#rid26">26</a>]. In animals, infection with a Nef-positive virus induces plexiform lesions typical of PAH, whereas infection with a Nef-negative virus does not. In another study patients with HIV-PAH had an increased number of HIV-nef gene polymorphisms when compared with patients who had HIV without PAH [<a href="#rid27">27</a>].</p><p></p><p>While coinfection with human herpes virus 8 (HHV-8) has been suggested to play a role in HIV-PAH, it is not involved in the development of IPAH suggesting that this hypothesis is unlikely [<a href="#rid28">28-31</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Host factors</span><span class="headingEndMark"> — </span>Individuals who have a specific human leukocyte antigen (HLA) may be predisposed to HIV-PAH. In a case-control study, the frequency of HLA class II DR52 and DR6 was increased among patients with HIV-PAH, compared with both healthy patients and patients with HIV without PAH [<a href="#rid32">32</a>].</p><p>Numerous host inflammatory cytokines are increased in patients with HIV infection. Examples include interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and platelet-derived growth factor, which together can induce a procoagulant state, increase the expression of endothelial adhesion molecules, and increase the accumulation of inflammatory cells in the pulmonary arteries [<a href="#rid33">33-35</a>]. However, these cytokines are unlikely to be the sole cause of HIV-PAH because they are elevated in all patients with HIV infection, only a fraction of whom develop PAH.</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2205203274"><span class="h2">Suspecting PAH</span><span class="headingEndMark"> — </span>In most patients, the diagnosis of HIV infection is already present. Thus, PAH should be suspected in patients with HIV who present with new symptoms and signs suggestive of PAH. Rarely, HIV is discovered during the routine evaluation of pulmonary hypertension (PH). The clinical presentation is identical to that associated with other types of PAH, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p>The average duration from the detection of HIV infection until the onset of PAH-related symptoms is roughly two years, occasionally longer [<a href="#rid2">2,36</a>]. However, PAH can occur in the early and late stages of HIV infection [<a href="#rid7">7</a>].</p><p>Accurate predictors for PAH development in HIV-infected patients are lacking:</p><p class="bulletIndent1"><span class="glyph">●</span>One study reported that plasma HIV-RNA, chronic hepatitis C, previous drug addiction, or female sex increased the risk of developing PAH by three-fold [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have reported a higher prevalence in men, perhaps reflecting the higher prevalence of HIV in men [<a href="#rid8">8,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One French cohort of HIV-PAH patients reported a high prevalence of drug abuse (59 percent) in this population suggesting that drug abuse was a risk factor for the development of PAH in HIV patients [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">Ritonavir</a> was suggested in one study as a risk factor for the development of PAH but the data to support this risk is poor and should not prevent clinicians from prescribing it for the treatment of HIV [<a href="#rid39">39</a>].</p><p></p><p>The CD4 count does not predict the likelihood of developing HIV-PAH or its hemodynamic severity.</p><p>Given the low rate of PAH in HIV, routine screening of asymptomatic patients with echocardiography has not been typically performed for early detection. However, guidelines from the 2018 6<sup>th</sup> world symposium on pulmonary hypertension suggest performing echocardiography in patients who are symptomatic or who have more than one risk factor (eg, female sex, hepatitis C infection, known Nef or Tat mutations, origin from a high-prevalence country, and/or African-American) as a way to enrich the likelihood of earlier diagnosis [<a href="#rid1">1</a>].</p><p>Patients with HIV-PAH may present with more severe PAH. One study reported that 55 percent of patients with HIV-PAH present with advanced ventricular dysfunction, compared with PAH patients from other etiologies [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of HIV-PAH requires confirmation of PAH and exclusion of alternative causes of PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) as well as confirmation of HIV infection:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirming PAH and excluding alternative causes of PH – The evaluation of patients with suspected HIV-PAH is similar to that in uninfected patients with PAH, during which, alternative types of PH (group 2 through 5) are excluded. Although 18 percent of patients with HIV-PAH have contributing etiologies (eg, chronic liver disease, drug abuse), distinguishing among the relative contributions of each is not feasible [<a href="#rid2">2</a>]. The diagnostic evaluation and criteria for patients with suspected PAH is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial diagnostic evaluation (noninvasive testing)'</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 1: Pulmonary arterial hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirming HIV infection – HIV infection is usually confirmed by a testing algorithm that uses an antigen/antibody combination HIV-1/HIV-2 immunoassay plus a confirmatory HIV-1/HIV-2 antibody differentiation test, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Patients with HIV-PAH should be treated with general measures which target factors contributing to the PAH and sequelae of the PAH  (<a class="graphic graphic_algorithm graphicRef116735" href="/d/graphic/116735.html" rel="external">algorithm 1</a>). Some patients may also be candidates for PAH-directed therapy, which targets the PAH itself. Although treatment is very similar to that in uninfected individuals with PAH, there are subtle difference for patients with HIV-PAH, which is the focus of this section. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H2986184190"><span class="h2">General measures</span></p><p class="headingAnchor" id="H2595967280"><span class="h3">Antiretroviral therapy</span><span class="headingEndMark"> — </span>Antiretroviral therapy (ART) should be offered to all HIV-infected patients, regardless of their CD4 count and irrespective of whether or not PAH is present. ART results in sustained suppression of HIV-RNA, improved cellular immunity (ie, CD4 count), reduced HIV-immune activation (eg, proinflammatory cytokines, chronic inflammation, and T-cell activation), and decreased HIV transmission to others. More detailed discussions of when to initiate therapy and how to choose a regimen are found elsewhere. (See  <a class="medical medical_review" href="/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p>The benefit of ART in treating HIV-PAH is unclear since data reporting the safety and efficacy of ART in this population are conflicting, and are from small retrospective studies that used older ART regimens (eg, the studies were conducted before the widespread use of integrase strand transfer inhibitors). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective analysis of 35 patients with HIV-PAH, combination ART therapy resulted in improved pulmonary pressures (median decrease of 25 mmHg in right ventricle:right atrial [RV:RA] pressure gradient on Doppler echocardiography), when compared with single agent therapy (decrease RV:RA gradient 3 mmHg), or no therapy (increase in RV:RA gradient 25 mmHg) [<a href="#rid41">41</a>]. In addition, there were fewer deaths attributable to PAH among patients who received combination ART compared with no therapy (5 versus 38 percent). These results should be interpreted with caution because the pressures were not measured directly by right heart catheterization; in addition the patients who received combination ART were managed during a different therapeutic era for PAH and were, therefore, more likely to receive prostanoid therapy as opposed to other PAH therapies that are now available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study reported that ART improved exercise capacity without significant changes in pulmonary hemodynamics [<a href="#rid42">42</a>]. Antiretroviral agents used in these regimens included <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9351" href="/d/drug information/9351.html" rel="external">didanosine</a>, <a class="drug drug_general" data-topicid="8558" href="/d/drug information/8558.html" rel="external">indinavir</a> plus <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, and <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study in an Indian cohort, which was conducted from 2008 to 2011, suggested hemodynamic benefits in patients with World Health Organization (WHO) functional class I and II  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 2</a>) but not in those with advanced disease [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a cohort study of 82 patients with HIV-PAH, which enrolled patients from 1986 to 2000, found that in the absence of <a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">epoprostenol</a>, survival worsened when patients were begun on ART, compared to improved survival when epoprostenol was included in the treatment regimen [<a href="#rid38">38</a>].</p><p></p><p>The effect of specific antiretroviral agents on the progression of PAH is unclear. In one study of HIV-infected individuals, among the 656 patients who had pulmonary hypertension (PH) identified by echocardiography, the protease inhibitor, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, was independently associated with the development of PH (odds ratio [OR] 1.75) [<a href="#rid39">39</a>], while another study reported that non-nucleoside reverse transcriptase inhibitors were not associated with the worsening of PAH [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1893846417"><span class="h3">Conventional and supportive therapies</span><span class="headingEndMark"> — </span>Similar to patients with group 1 PAH, all patients with HIV-PAH should exercise as tolerated, receive routine vaccinations  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 2</a>), be counseled against smoking and pregnancy, and be treated with supportive measures including oxygen and diuretics, when indicated. We do <strong>not routinely</strong> anticoagulate patients with HIV-PAH, since data are conflicting in the non-HIV population. Evidence to support this approach is typically extrapolated from patients with non-HIV-related PAH, the details of which are discussed separately. (see  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a> and  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>)</p><p class="headingAnchor" id="H701062313"><span class="h2">WHO functional class I</span></p><p class="headingAnchor" id="H325411212"><span class="h3">Observation</span><span class="headingEndMark"> — </span>WHO functional class I patients  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 2</a>) do not require pharmacologic therapy; however, they should be clinically monitored (eg, every three to six months) for disease progression to a functional level that may warrant therapy.</p><p class="headingAnchor" id="H3097033934"><span class="h2">WHO functional class II-IV</span><span class="headingEndMark"> — </span>Similar to patients with non-HIV-related PAH, patients with WHO functional class II, III, or IV  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 2</a>) should be referred to a specialized center to be evaluated for PAH-specific therapy. PAH-specific therapy is directed at PAH itself rather than the underlying cause. Therapy is determined by many factors, particularly WHO functional class  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 2</a>) as well as potential interactions with the patients HIV medications. Comanagement with both a pulmonary hypertension (PH) expert and an HIV expert is recommended. The evidence supporting PAH-specific therapy comes primarily from studies that included mostly patients with idiopathic PAH (IPAH) with only a small proportion (&lt;25 percent) or no patients with HIV-PAH included in the analyses (see  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Definition'</a>). Evidence to support similar benefits in patients with HIV-PAH is limited and is the focus of this section.</p><p class="headingAnchor" id="H1865484107"><span class="h3">Pulmonary arterial hypertension-directed therapy</span></p><p class="headingAnchor" id="H967324548"><span class="h4">Agent selection</span><span class="headingEndMark"> — </span>There are several classes of agents including endothelin receptor antagonists, nitric oxide (NO) cyclic guanosine monophosphate (GMP) enhancers (phosphodiesterase inhibitors and guanylate cyclase stimulants), and prostacyclin pathway agonists  (<a class="graphic graphic_table graphicRef50798" href="/d/graphic/50798.html" rel="external">table 3</a>). In general, the principles of agent selection are similar to that in the non-HIV-infected PAH population with special considerations in HIV-infected patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium channel blockers (CCBs) should be avoided. (See <a class="local">'Avoidance of calcium channel blockers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain endothelin receptor antagonists and phosphodiesterase inhibitors may require dose adjustments if the patient is on an ART regimen that includes a pharmacologic boosting agent (ie, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>). A shared decision by the patient, and PH and HIV experts that weighs the risks of drug interactions and benefits of a specific therapy is critical. Specific drug interactions and management suggestions may be determined by using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See <a class="local">'Endothelin receptor antagonists'</a> below and <a class="local">'Phosphodiesterase inhibitors'</a> below.)</p><p></p><p>Further details regarding agent selection in patients with non-HIV-PAH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'WHO functional class II and III or low/intermediate risk (combination oral therapy)'</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'WHO functional class IV or high risk (parenteral prostanoid-containing combination regimen)'</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H1032999575"><span class="h4">Avoidance of calcium channel blockers</span><span class="headingEndMark"> — </span>In contrast to patients with PAH who have positive vasoreactivity testing and do not have HIV, patients with HIV-PAH are not typically treated with CCBs. However, although anecdotal cases of CCB responses exist, their administration is extremely rare and the approach should be cautious. This approach is based upon the observation that vasoreactivity only occurs in a small proportion of HIV-PAH patients (approximately 1.6 percent) and long-term response to CCBs has been reported in only a small number of those patients. In addition, intolerable side effects including hypotension and interaction with antiretroviral therapy, especially protease inhibitors, can develop in this population [<a href="#rid10">10,44,45</a>]. Since CCBs are not typically prescribed, patients with HIV-PAH do not need to undergo routine vasoreactivity testing. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactive patients'</a>.)</p><p class="headingAnchor" id="H1432544467"><span class="h4">Combination therapy</span><span class="headingEndMark"> — </span>Combining agents from two classes is commonly used in patients with group 1 PAH but has not been specifically studied in patients with HIV-PAH. Nonetheless, the principles of agent selection are similar such that most patients with HIV-PAH and WHO functional class II, III, and IV should receive combination therapy. However, the major difference is that agents are typically added sequentially due to the potential for drug interaction. Further details regarding PAH-specific therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H1643436694"><span class="h4">Endothelin receptor antagonists</span><span class="headingEndMark"> — </span>There are limited data supporting use of endothelin receptor antagonists (ERAs) in patients with HIV-PAH.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">Bosentan</a> — Several trials have shown benefits with bosentan [<a href="#rid42">42,46,47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one uncontrolled clinical trial of 16 patients with HIV-PAH, 16 weeks of oral <a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">bosentan</a> resulted in improved exercise capacity, functional class, mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index (CI), right ventricle size and function, and quality of life [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A subsequent retrospective study evaluated the effects of <a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">bosentan</a> in patients with HIV-PAH over a longer duration [<a href="#rid47">47</a>]. The study enrolled 59 patients (12 from the above study); 56 patients were evaluated after four months of therapy and 38 were evaluated over a mean of 29 months. The improvements in exercise capacity, PVR, and functional class persisted for at least 2.5 years. Survival at 1, 2, and 3 years was 93, 86, and 66 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8653" href="/d/drug information/8653.html" rel="external">Ambrisentan</a> and <a class="drug drug_general" data-topicid="91206" href="/d/drug information/91206.html" rel="external">macitentan</a> – These selective ERAs have been insufficiently studied in patients with HIV-PAH with only small numbers of HIV patients included in larger trials (ARIES [Ambrisentan] [<a href="#rid48">48</a>] and SERAPHIN [macitentan] [<a href="#rid49">49</a>]).</p><p></p><p>If <a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">bosentan</a> is used, dose modifications are required in patients who are receiving an ART regimen that includes a pharmacologic boosting agent (<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>; refer to the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate for specific recommendations). In contrast, <a class="drug drug_general" data-topicid="8653" href="/d/drug information/8653.html" rel="external">ambrisentan</a> does not need any dose adjustments. There are no data on how to manage <a class="drug drug_general" data-topicid="91206" href="/d/drug information/91206.html" rel="external">macitentan</a> and an alternative ERA should generally be used, or the ART regimen modified, if possible. (See  <a class="medical medical_review" href="/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"</a>.)</p><p>Further data supporting efficacy of these agents in patients with non-HIV-related PAH (mostly IPAH) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H1643436613"><span class="h4">Nitric oxide-cyclic guanosine monophosphate enhancers</span><span class="headingEndMark"> — </span>Agents in this class include phosphodiesterase type 5 (PDE5) inhibitors and guanylate cyclase stimulants. Limited data in patients with HIV-PAH demonstrate improvement in pulmonary hemodynamics, functional class, and exercise capacity.</p><p class="headingAnchor" id="H138465640"><span class="h5">Phosphodiesterase inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">Sildenafil</a> – Although there have been case reports suggesting that sildenafil can improve symptoms and hemodynamics in patients with HIV-PAH, the preponderance of evidence suggests that it should be avoided in those receiving an ART regimen that includes a pharmacologic boosting agent, such as <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>. Boosting agents are used in combination with protease inhibitors or the integrase strand transfer inhibitor <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>. This approach is due to the fact that sildenafil significantly decreases protease inhibitor levels and that the boosting agents significantly increase sildenafil levels [<a href="#rid47">47,50-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10108" href="/d/drug information/10108.html" rel="external">Tadalafil</a><strong> and </strong><a class="drug drug_general" data-topicid="10172" href="/d/drug information/10172.html" rel="external">Vardenafil</a> – Other PDE5 inhibitors (tadalafil and vardenafil) have not been adequately studied in patients with HIV-PAH, although one trial of 18 patients with HIV-PAH (on different classes on PAH-directed therapy) included three patients taking tadalafil [<a href="#rid36">36</a>]; no specific adverse effect were reported. In our experience, when tadalafil (usually in combination with <a class="drug drug_general" data-topicid="8653" href="/d/drug information/8653.html" rel="external">ambrisentan</a>) is indicated and the patient is on a regimen that contains a pharmacologic boosting agent (eg, pharmacologically boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="105353" href="/d/drug information/105353.html" rel="external">elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide</a>), most experts will consider the feasibility of switching antiretroviral therapy to a regimen that does not include a boosting agent. Alternatively, the dose of tadalafil can be adjusted (refer to the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate for specific information).</p><p></p><p>Further data supporting their efficacy in patients with non-HIV-related PAH (mostly IPAH) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H817299401"><span class="h5">Guanylate cyclase stimulant</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91067" href="/d/drug information/91067.html" rel="external">Riociguat</a> is a guanylate cyclase stimulant of proven benefit in patients with chronic thromboembolic pulmonary hypertension. It has not been studied in patients with HIV-PAH but trials are underway. Given the cytochrome CYP inhibition of protease inhibitors, riociguat levels would increase with concomitant use, but the clinical significance is unknown, although limited data suggest reasonable tolerance of riociguat in this population [<a href="#rid55">55</a>]. Thus, we feel that riociguat should be avoided until more information is available. (See  <a class="medical medical_review" href="/d/html/16628.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy", section on 'Medication selection'</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H1579564854"><span class="h4">Prostacyclin pathway agonists</span><span class="headingEndMark"> — </span>Limited data in patients with HIV-PAH demonstrate improvement in pulmonary hemodynamics, functional class, and exercise capacity with prostacyclin pathway agonists.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">Epoprostenol</a> – Several trials have shown efficacy of epoprostenol in patients with HIV-PAH [<a href="#rid38">38,56-61</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an uncontrolled clinical trial of six patients with HIV-PAH, intravenous <a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">epoprostenol</a> resulted in a reduction in the mPAP by 8.5 mmHg and PVR by 216 dynes/sec per cm<sup>-5</sup>), an increase in the cardiac output by 2 L/min and CI by 1.1 L/min per m<sup>2</sup>, and improvement in functional class  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 2</a>) [<a href="#rid58">58</a>]. Repeat catheterization of five patients after one year demonstrated further improvement in pulmonary hemodynamics  (<a class="graphic graphic_figure graphicRef64309" href="/d/graphic/64309.html" rel="external">figure 3</a>) which continued for up to four years (two patients). The frequency of adverse effects and complications were similar compared with that reported in patients with IPAH. Although five of the six patients died, none of the deaths were due to PAH.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhaled <a class="drug drug_general" data-topicid="9411" href="/d/drug information/9411.html" rel="external">epoprostenol</a> was evaluated in two patients with HIV-PAH [<a href="#rid57">57</a>]. Seven months of inhaled epoprostenol therapy was associated with improved exercise capacity, functional class, mPAP, and PVR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10207" href="/d/drug information/10207.html" rel="external">Treprostinil</a> – In an uncontrolled clinical trial of three patients with HIV-PAH, subcutaneous treprostinil resulted in improved exercise capacity and functional class at one year [<a href="#rid61">61</a>]. In addition, the systolic pulmonary artery pressure (estimated by echocardiography) improved in two of the patients. No serious adverse events were observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8895" href="/d/drug information/8895.html" rel="external">Iloprost</a> – In an uncontrolled trial of eight patients with HIV-PAH, inhaled iloprost resulted in acute improvement of the PVR and CI [<a href="#rid60">60</a>]. Hemodynamic improvement persisted and exercise capacity also improved in the four patients who continued with long-term iloprost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="106041" href="/d/drug information/106041.html" rel="external">Selexipag</a> – This oral agent has not been specifically tested in HIV-PAH.</p><p></p><p>Further data supporting efficacy of these agents in patients with non-HIV-related PAH (mostly IPAH) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H1153332491"><span class="h2">Refractory disease</span></p><p class="headingAnchor" id="H52819126"><span class="h3">Right to left shunts and lung transplantation</span><span class="headingEndMark"> — </span>While shunts may be appropriate (eg, atrial septostomy) in those with severe symptomatic HIV-PAH that is refractory to combination therapy, HIV is typically considered by most transplant centers as a relative contraindication to lung transplantation. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Lung transplantation'</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Right-to-left shunt'</a>.)</p><p class="headingAnchor" id="H2925138329"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Mortality was originally high among patients with HIV-PAH but is improving in the era of PAH-directed therapy and antiretroviral therapy (ART). Although not directly compared, the outcome approaches that of patients with idiopathic PAH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). Compared with patients with HIV who do not have PAH, HIV-PAH is an independent predictor of death. (See  <a class="medical medical_review" href="/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p>Data from the early 2000s suggested high mortality ranging from roughly 27 to 66 percent [<a href="#rid2">2,38,41,62</a>]. In contrast, data after 2010 suggest improved mortality rates. In a series of 77 patients with HIV-PAH, the one- and three-year survival rates were 88 and 72 percent, respectively [<a href="#rid63">63</a>]. All of the patients in the series received ART and 50 patients (65 percent) received PAH-directed therapy.</p><p>Although data are limited, it is well established that PAH in the setting of HIV is an independent risk factor for death [<a href="#rid62">62</a>]. Data also support that HIV-PAH prognosis is worse than that of idiopathic PAH [<a href="#rid6">6,64</a>].</p><p>A low CD4 count may be associated with increased mortality due to HIV-PAH [<a href="#rid38">38,63</a>]. Otherwise, it is assumed that poor prognostic indicators are similar to those in non-HIV-related PAH. (See  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p class="headingAnchor" id="H1179012466"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Human immunodeficiency virus-related pulmonary arterial hypertension (HIV-PAH) refers to pulmonary arterial hypertension (PAH) that develops in a patient who has HIV infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Although PAH is a rare complication of HIV infection, it is more prevalent than PAH is among HIV-uninfected individuals. Furthermore, studies likely underestimate its true prevalence. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Pathogenetic mechanisms are likely shared between HIV- and idiopathic PAH. Additional HIV-specific factors also likely play an important role, although the relative contributions host and viral factors are difficult to discern since many patients with HIV infection have coexisting conditions that are independently associated with PAH (eg, intravenous drug use or chronic liver disease). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Most patients with HIV-PAH have known HIV infection and present with new symptoms related to PAH (eg, progressive dyspnea). Diagnosis of HIV-PAH requires confirmation of PAH by right heart catheterization, the exclusion of group 2, 3, 4, and 5 pulmonary hypertension (PH)  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), and confirmation of HIV infection by serologic testing. (See <a class="local">'Diagnostic evaluation'</a> above and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 1: Pulmonary arterial hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – In patients with HIV-related PAH, treatment with general measures and PAH-specific therapies (endothelin receptor antagonists, nitric oxide-cyclic guanosine monophosphate enhancers [phosphodiesterase inhibitors and guanylate cyclase stimulants], and prostacyclin pathway agonists  (<a class="graphic graphic_table graphicRef50798" href="/d/graphic/50798.html" rel="external">table 3</a>)) are nearly identical to that for other types of PAH. However, data to support select agents is limited in patients with HIV-PAH. In addition, when combination therapy is used, we prefer add in (sequential) therapy to monitor adequately for drug interactions. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p></p><p class="bulletIndent1">Aspects of treatment that are unique to patients with HIV-PAH include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no evidence that antiretroviral therapy (ART) is beneficial for the treatment of HIV-PAH. However, most patients with HIV infection are treated with ART irrespective of whether or not PAH is present. (See <a class="local">'Antiretroviral therapy'</a> above and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do <strong>not</strong> routinely anticoagulate patients with HIV-PAH since there are no direct data in HIV infected patients that report benefit and indirect data from non-HIV-PAH populations are conflicting. (See <a class="local">'Conventional and supportive therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with HIV-PAH do <strong>not</strong> need to undergo vasoreactivity testing since calcium channel blocker (CCB) therapy is rarely of benefit and may be associated with an increased risk of adverse effects when compared with uninfected patients with PAH. (See <a class="local">'Avoidance of calcium channel blockers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9254" href="/d/drug information/9254.html" rel="external">Bosentan</a> (endothelin receptor antagonist) and <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a> (phosphodiesterase inhibitor) should be avoided in patients taking pharmacologically boosted regimens (eg, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> and cobicistat-containing regimens) due to the likelihood that drug-drug interactions (DDIs) alter the efficacy of both ART and PAH regimens. Alternatively, switching antiretroviral therapy to a regimen that does not include a boosting agent, is appropriate, if feasible. Although data are less robust for similar DDIs, we suggest the same approach for patients who are potential candidates for <a class="drug drug_general" data-topicid="91206" href="/d/drug information/91206.html" rel="external">macitentan</a>, <a class="drug drug_general" data-topicid="10108" href="/d/drug information/10108.html" rel="external">tadalafil</a> and <a class="drug drug_general" data-topicid="91067" href="/d/drug information/91067.html" rel="external">riociguat</a>. Alternatively, dose adjustments can be made with close follow-up of CD4 counts and viral levels. Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> within UpToDate for specific recommendations. (See <a class="local">'Agent selection'</a> above and <a class="local">'Endothelin receptor antagonists'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe end-stage HIV-PAH, HIV infection is typically considered a relative contraindication to lung transplantation. (See <a class="local">'Right to left shunts and lung transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prognosis – The outcome of HIV-PAH has improved and is now approaching that of patients with idiopathic PAH. However, among patients with HIV, HIV-PAH is an independent predictor of mortality. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133.</a></li><li><a class="nounderline abstract_t">Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023.</a></li><li><a class="nounderline abstract_t">Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268.</a></li><li><a class="nounderline abstract_t">Barbarinia G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003; 17 Suppl 1:S46.</a></li><li><a class="nounderline abstract_t">Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108.</a></li><li><a class="nounderline abstract_t">Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73:37.</a></li><li><a class="nounderline abstract_t">Himelman RB, Dohrmann M, Goodman P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64:1396.</a></li><li><a class="nounderline abstract_t">Isasti G, Moreno T, Pérez I, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29:231.</a></li><li><a class="nounderline abstract_t">Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155:990.</a></li><li><a class="nounderline abstract_t">Pellicelli AM, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001; 52:31.</a></li><li><a class="nounderline abstract_t">Quezada M, Martin-Carbonero L, Soriano V, et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012; 26:1387.</a></li><li><a class="nounderline abstract_t">Schwarze-Zander C, Pabst S, Hammerstingl C, et al. Pulmonary hypertension in HIV infection: a prospective echocardiographic study. HIV Med 2015; 16:578.</a></li><li><a class="nounderline abstract_t">Bigna JJ, Nansseu JR, Um LN, et al. Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis. BMJ Open 2016; 6:e011921.</a></li><li><a class="nounderline abstract_t">Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS 2012; 26:1967.</a></li><li><a class="nounderline abstract_t">Brittain EL, Duncan MS, Chang J, et al. Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. Am J Respir Crit Care Med 2018; 197:923.</a></li><li><a class="nounderline abstract_t">Cerrato E, D'Ascenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34:1432.</a></li><li><a class="nounderline abstract_t">Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145:1196.</a></li><li><a class="nounderline abstract_t">Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11:554.</a></li><li><a class="nounderline abstract_t">Burkart KM, Farber HW. HIV-associated pulmonary hypertension: diagnosis and treatment. Adv Cardiol 2003; 40:197.</a></li><li><a class="nounderline abstract_t">Dalvi P, O'Brien-Ladner A, Dhillon NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2013; 33:2585.</a></li><li><a class="nounderline abstract_t">Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150:4601.</a></li><li><a class="nounderline abstract_t">Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 2011; 12:103.</a></li><li><a class="nounderline abstract_t">Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol 2006; 79:192.</a></li><li><a class="nounderline abstract_t">Guo ML, Kook YH, Shannon CE, Buch S. Notch3/VEGF-A axis is involved in TAT-mediated proliferation of pulmonary artery smooth muscle cells: Implications for HIV-associated PAH. Cell Death Discov 2018; 4:22.</a></li><li><a class="nounderline abstract_t">Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006; 174:437.</a></li><li><a class="nounderline abstract_t">Almodovar S, Knight R, Allshouse AA, et al. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses 2012; 28:607.</a></li><li><a class="nounderline abstract_t">Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349:1113.</a></li><li><a class="nounderline abstract_t">Henke-Gendo C, Mengel M, Hoeper MM, et al. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005; 172:1581.</a></li><li><a class="nounderline abstract_t">Katano H, Hogaboam CM. Herpesvirus-associated pulmonary hypertension? Am J Respir Crit Care Med 2005; 172:1485.</a></li><li><a class="nounderline abstract_t">Montani D, Marcelin AG, Sitbon O, et al. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005; 19:1239.</a></li><li><a class="nounderline abstract_t">Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996; 153:1299.</a></li><li><a class="nounderline abstract_t">Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1628.</a></li><li><a class="nounderline abstract_t">Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946:82.</a></li><li><a class="nounderline abstract_t">Tcherakian C, Couderc LJ, Humbert M, et al. Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. Semin Respir Crit Care Med 2013; 34:645.</a></li><li><a class="nounderline abstract_t">Araújo I, Enjuanes-Grau C, Lopez-Guarch CJ, et al. Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. World J Cardiol 2014; 6:495.</a></li><li><a class="nounderline abstract_t">Myerson M, Poltavskiy E, Armstrong EJ, et al. Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients. J Acquir Immune Defic Syndr 2014; 66:370.</a></li><li><a class="nounderline abstract_t">Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433.</a></li><li><a class="nounderline abstract_t">Mondy KE, Gottdiener J, Overton ET, et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis 2011; 52:378.</a></li><li><a class="nounderline abstract_t">Dellegrottaglie S, García-Alvarez A, Guarini P, et al. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. Heart Lung 2014; 43:256.</a></li><li><a class="nounderline abstract_t">Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178.</a></li><li><a class="nounderline abstract_t">Barbaro G, Lucchini A, Pellicelli AM, et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92:1164.</a></li><li><a class="nounderline abstract_t">Pal J, Sen K, Sarkar G, et al. Effect of antiretroviral therapy on pulmonary hypertension in HIV patients. J Indian Med Assoc 2013; 111:845.</a></li><li><a class="nounderline abstract_t">Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105.</a></li><li><a class="nounderline abstract_t">Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31:1898.</a></li><li><a class="nounderline abstract_t">Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212.</a></li><li><a class="nounderline abstract_t">Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33:92.</a></li><li><a class="nounderline abstract_t">Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010.</a></li><li><a class="nounderline abstract_t">Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809.</a></li><li><a class="nounderline abstract_t">Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16:1568.</a></li><li><a class="nounderline abstract_t">Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15:1747.</a></li><li><a class="nounderline abstract_t">Wong AR, Rasool AH, Abidin NZ, et al. Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42:147.</a></li><li><a class="nounderline abstract_t">Romanazzi S, Manes A, Hirani N, et al.. Sildenafil therapy for patients with pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med 2007; :A1001.</a></li><li><a class="nounderline abstract_t">Pergola V, Caruso C, Gnarini R, et al. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension. J Cardiovasc Med (Hagerstown) 2015; 16 Suppl 2:S136.</a></li><li><a class="nounderline abstract_t">DeJesus E, Saleh S, Cheng S, et al. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. Pulm Circ 2019; 9:2045894019848644.</a></li><li><a class="nounderline abstract_t">Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89:2722.</a></li><li><a class="nounderline abstract_t">Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med 1997; 127:1043.</a></li><li><a class="nounderline abstract_t">Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846.</a></li><li><a class="nounderline abstract_t">Farber HW. HIV-associated pulmonary hypertension. AIDS Clin Care 2001; 13:53.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004; 23:321.</a></li><li><a class="nounderline abstract_t">Cea-Calvo L, Escribano Subías P, Tello de Menesses R, et al. [Treatment of HIV-associated pulmonary hypertension with treprostinil]. Rev Esp Cardiol 2003; 56:421.</a></li><li><a class="nounderline abstract_t">Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008; 22 Suppl 3:S35.</a></li><li><a class="nounderline abstract_t">Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24:67.</a></li><li><a class="nounderline abstract_t">Henriques-Forsythe M, Annangi S, Farber HW. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. Pulm Circ 2015; 5:506.</a></li></ol></div><div id="topicVersionRevision">Topic 8246 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035689" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HIV-Related pulmonary hypertension: analytic review of 131 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16456139" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary arterial hypertension in France: results from a national registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935280" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary pulmonary hypertension in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870530" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of the involvement of the cardiovascular system in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932378" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443676" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2531539" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22849654" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9117037" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11205929" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary pulmonary hypertension in HIV patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526521" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25960172" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary hypertension in HIV infection: a prospective echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27554104" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781217" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29131651" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335603" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586065" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596101" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14533555" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : HIV-associated pulmonary hypertension: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24008158" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482849" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21819559" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypoxia-inducible factor-1α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282533" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30109141" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Notch3/VEGF-A axis is involved in TAT-mediated proliferation of pulmonary artery smooth muscle cells: Implications for HIV-associated PAH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728715" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22066947" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679525" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Expression of human herpesvirus 8 in primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444822" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Herpesvirus-associated pulmonary hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990583" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616557" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7735624" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762997" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pathogenesis of HIV-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037631" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24976921" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24732872" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615632" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21217185" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24680629" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095226" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844879" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154159" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of antiretroviral therapy on pulmonary hypertension in HIV patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939821" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543192" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317666" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799506" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506008" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23984728" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Macitentan and morbidity and mortality in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131202" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546958" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sildenafil in HIV-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509918" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sildenafil therapy for patients with pulmonary arterial hypertension associated with HIV infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635750" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of sildenafil in HIV-related pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30997864" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205687" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9412295" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prostacyclin for HIV-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069824" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11710309" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : HIV-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14979511" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12689580" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : [Treatment of HIV-associated pulmonary hypertension with treprostinil].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18845920" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770696" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26401251" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
